EUVIMEDEUVIMED entdecken
Crossref

Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure

Yingyan Lu, Jiaojiao Xin, Xi Liang, Jinjin Luo, Peng Li, Xingping Zhou, Hui Yang, Jun Li, Yifan Wang

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Yingyan Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute of Integrative Medicine, Zhejiang Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine…. Hauptthemen laut MEDLINE: c-Mer Tyrosine Kinase, Acute-On-Chronic Liver Failure, Biomarkers, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Basic Public Welfare Research Project of Zhejiang Province, Zhejiang Provincial Medical and Health Science and Technolog, Zhejiang Provincial Medical and Health Science and Technology Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis B virus–related acute-on-chronic liver failure (HBV-ACLF) has a high short-term mortality. This study aimed to determine the diagnostic and prognostic role of MER tyrosine kinase (MERTK) in patients with HBV-ACLF.

Methods

Transcriptomics analysis evaluated MERTK expression and function during disease progression. The diagnostic and prognostic significance of MERTK for patients with HBV-ACLF were verified by enzyme-linked immunosorbent assay, area under the receiver operating characteristic curve (AUROC) analysis, and immunohistochemistry (IHC) of liver tissues.

Results

MERTK mRNA was highly expressed in patients with HBV-ACLF compared to those with liver cirrhosis (LC), chronic hepatitis B (CHB), and normal controls (NC). Elevated MERTK mRNA predicted poor prognosis for HBV-ACLF at 28 and 90 days (AUROC = 0.814 and 0.731, respectively). Functional analysis showed MERTK was significantly associated with toll-like receptor and inflammatory signaling and several key biological processes. External validation with 285 plasma subjects confirmed the high diagnostic accuracy of plasma MERTK for HBV-ACLF (AUROC = 0.859) and potential prognostic value for 28- and 90-day mortality rates (AUROC = 0.673 and 0.644, respectively). Risk stratification analysis indicated higher mortality risk for patients with plasma MERTK level above the cutoff value. Moreover, IHC staining showed increasing MERTK expression from NC, CHB, and LC to HBV-ACLF.

Conclusions

MERTK shows promise as a candidate biomarker for early diagnosis and prognosis of HBV-ACLF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

c-Mer Tyrosine KinaseAcute-On-Chronic Liver FailureBiomarkersHepatitis B, ChronicHumansMalePrognosisFemaleAdultMiddle AgedHepatitis B virusLiverROC Curve

Stichwörter der Autor:innen

HBV-ACLFMERTKbiomarkerdiagnosisprognosis

Substanzen

c-Mer Tyrosine KinaseMERTK protein, humanBiomarkers

Autor:innen und Institutionen

  • Cancer Institute of Integrative Medicine, Zhejiang Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of…
  • State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative National Clinical Research Center for Infectious Diseases, The First Affi…
  • Precision Medicine Center, Taizhou Central Hospital, Taizhou University Hospital, Taizhou, China.

Förderung

  • Basic Public Welfare Research Project of Zhejiang Province
  • Zhejiang Provincial Medical and Health Science and Technolog
  • Zhejiang Provincial Medical and Health Science and Technology Plan

Zitieren

APA

Lu, Y., Xin, J., Liang, X., Luo, J., Li, P., Zhou, X., Yang, H., Li, J., & Wang, Y. (2024). Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae079

Vancouver

Lu Y, Xin J, Liang X, Luo J, Li P, Zhou X, et al. Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae079

BibTeX
@article{Lu2024,
  author = {Lu, Yingyan and Xin, Jiaojiao and Liang, Xi and Luo, Jinjin and Li, Peng and Zhou, Xingping and Yang, Hui and Li, Jun and Wang, Yifan},
  title = {Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae079}
}
Kostenlos starten →